Abstract
Nephropathy refers to a wide range of kidney dysfunction and is a highly prevalent condition worldwide, often associated with several disorders, including inflammation, oxidative stress, apoptosis, epithelial-mesenchymal transition (EMT), autophagy, and the deposition of extracellular matrix (ECM). Licorice has been used in China for thousands of years to treat nephropathy, while the underlying mechanisms are still unclear. The triterpenoid and flavonoid compounds are the main components of licorice. The main bioactive components of licorice against nephropathy are glycyrrhizic acid, glycyrrhetinic acid, isoliquiritigenin, glabridin, isoliquiritin and licochalcone A. These components alleviate kidney injury through anti-inflammatory, anti-oxidative stress, anti-apoptosis, promoting autophagy, inhibiting EMT, and reducing ECM deposition by targeting the signaling pathways of NF-κB, TGF-β1, JNK, MAPK, p53, STAT3 and HMGB1. This review will provide a new insight to clarify the bioactive components of licorice against nephropathy and their corresponding mechanisms, which aims to provide useful information for the further application of licorice.
1 Introduction
Nephropathy refers to various disorders of the kidney, with clinical manifestations including proteinuria, hematuria, hypertension, and renal insufficiency (). The average prevalence of chronic kidney diseases (CKD) is approximately 13.4% worldwide, and it shows an increasing trend year by year (; ). The global morbidity rate of CKD is approximately 9.5%, and the mortality rate is approximately 2.66% (; Xie et al., 2025). Without effective strategy, CKD will lead to end-stage renal disease and ultimately to renal failure, which will require the treatment with dialysis or kidney transplantation (; ; Yan and Shao, 2024). However, it is difficult to find a suitable kidney donor. In addition, the cost is vast. Therefore, drug therapy may be a better choice. The drugs, used in clinic to treat kidney diseases such as the angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, show some side effects, which limit their clinical use (; Zhu et al., 2022). Thus, drugs specific for kidney diseases should be developed. Many factors can lead to nephropathy, such as infection, hypertension, toxin, diabetes and obesity (; ; ). The damaged kidney often shows some disorders, including inflammation, oxidative stress, apoptosis, epithelial-mesenchymal transition (EMT), autophagy and the deposition of extracellular matrix (ECM) (; ; ; ; ; ). Drugs alleviating these disorders will be therapeutic for nephropathy.
Nephropathy is primarily identified as urinary obstruction, severe urinary retention and nephrotoxicity in the theory of traditional Chinese medicine (TCM) (; Wang et al., 2022). TCM shows a significant therapy effect on nephropathy by promoting blood circulation to remove blood stasis and clearing heat and dampness. Licorice is a key TCM in the treatment of nephropathy, while the underlying mechanisms are still unclear ().
Licorice is derived from the dried roots and rhizomes of leguminous plants Glycyrrhiza uralenssis Fish., Glycyrrhiza inflate Bat. and Glycyrrhiza glabra L. (Wahab et al., 2021; ; ). It is mainly distributed in Inner Mongolia, Xinjiang and Gansu provinces in China. It has the functions of clearing heat and detoxifying, as well as expelling phlegm and relieving cough (Wu et al., 2010). The compounds derived from licorice not only exhibit renoprotective efficacy comparable to those of clinical drugs such as rosiglitazone, but also significantly cheaper, indicating a promising prospect for use as drugs ().
In order to clarify the material basis and mechanisms of licorice in treating kidney diseases, this review focuses on the main components of licorice against kidney diseases and their corresponding mechanisms, which will provide useful information for its application in the treatment of nephropathy.
2 Chemical components of licorice
A great number of compounds have been isolated and characterized from licorice (Supplementary Table S1). These compounds are mainly composed of flavonoids, triterpenoids, coumarins, phenols, and alkanes constituents (Supplementary Table S1). The triterpenoids and flavonoids are the principal active constituents of licorice.
The triterpenoids are the most abundant constituents in licorice, predominantly existing as oleanane-type triterpenes (Supplementary Table S1). These compounds often show anti-inflammatory, antitumor, and antiviral activities. Glycyrrhizic acid is the most important bioactive compound of licorice.
Licorice is rich in flavonoid constituents with diverse structures, encompassing flavones, isoflavones, dihydroflavones, chalcones, and flavanones (Supplementary Table S1). Flavonoids often exhibit various pharmacological properties, such as anti-inflammatory, antioxidant, antibacterial, antiviral, and antitumor properties.
3 Mechanisms of licorice against nephropathy
There are many mediators contribute to the development of nephropathy, such as the signaling pathways of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), transforming growth factor β1 (TGF-β1), signal transducer and activator of transcription 3 (STAT3), p53 and c-Jun N-terminal kinase (JNK). The compounds of licorice show a renoprotective effect on the damaged kidney by targeting these mediators. The following section compiles the mechanisms of action of selected active phytomolecules of licorice against nephropathy.
3.1 Inflammation
The inflammatory response is a defensive response of the body to tissue damage. Various cell types are involved in the inflammation response, including macrophages, T lymphocytes and B lymphocytes. Extensive studies reveal that the NF-κB and TGF-β1 signaling pathways play a key role in the progression of inflammation. When kidney is damaged, it can trigger inflammatory response. The early inflammation has a beneficial effect on tissue repair, while the chronic inflammation leads to kidney damage. Therefore, it is an effective strategy to suppress inflammation and alleviate kidney injury by inhibiting the NF-κB and TGF-β1 signaling pathways ().
3.1.1 NF-κB signaling pathway
Both the extracts and the compounds of licorice suppress inflammation by inhibiting the NF-κB signaling pathway in the process of nephropathy.
The aqueous extract of licorice alleviated membranous glomerulonephritis-induced by cationic bovine serum protein via inhibiting the NF-κB signaling pathway in rats, suggesting that the highly polar compounds of licorice may exhibit the anti-inflammatory activity (; ).
Multiple studies revealed that glycyrrhizic acid was the main anti-inflammatory component of licorice. It was reported that glycyrrhizic acid alleviated lipopolysaccharide (LPS)-induced inflammation in HBZY-1 cells and sepsis-induced inflammation in rats via inhibiting the NF-κB nuclear translocation (Figure 1; Table 1) (Zhao et al., 2016a; Zhao et al., 2016b). In addition, glycyrrhizic acid alleviated inflammation by down-regulating the NF-κB expression in acute kidney injury (AKI) mice (Table 1) (Wu et al., 2015). Moreover, glycyrrhizic acid protected against kidney injury via suppressing the NF-κB signaling pathway in insulin-resistant rats (Table 1) (). Furthermore, glycyrrhizic acid attenuated inflammation and fibrosis-induced by high glucose via the AMPK signaling pathway in mice (Table 1) (Zhao et al., 2023). These results indicate that glycyrrhizic acid improves inflammation by inhibiting the NF-κB and MAPK signaling pathways.
FIGURE 1
TABLE 1
| Compound | Cellular mechanism | Model | Signaling pathway | Reference |
|---|---|---|---|---|
| Glycyrrhizic acid | Inflammation | LPS-treated HBZY-1 cells | NF-κB | Zhao et al. (2016a) |
| Inflammation | Sepsis-treated rats | NF-κB | Zhao et al. (2016b) | |
| Inflammation | AKI mice | NF-κB | Wu et al. (2015) | |
| Inflammation | Insulin-resistant rats | NF-κB | ||
| Inflammation | High glucose-treated mice | AMPK | Zhao et al. (2023) | |
| Inflammation | Doxorubicin-treated rats | TGF-β1 | ||
| ECM deposition | Adriamycin-treated rats | TGF-β1 | Yu et al. (2010) | |
| Inflammation | Nicotine-induced podocyte injury | HMGB1 | ||
| Inflammation | Con A-treated mice | IL-25 | ||
| Oxidative stress | Cisplatin-treated HK-2 cells | p53 | ||
| Oxidative stress | Cisplatin-treated mice | Unknown | ||
| Oxidative stress | Renal carcinoma cells | Unknown | Wu et al. (2013) | |
| Oxidative stress | AKI rats | HMGB1 | ||
| Apoptosis | AKI mice | p38-MAPK | Ye et al. (2014) | |
| Autophagy | Tacrolimus-treated mice | Unknown | ||
| ECM deposition | Adriamycin-treated rats | Unknown | Wang et al. (2006) | |
| Other | Acute ischemia/reperfusion-treated rats | PI3K/AKT | ||
| Glycyrrhetinic acid | ECM deposition | Diabetic nephropathy mice | Unknown | |
| EMT | Diabetic nephropathy mice | α-SMA/E-cadherin | ||
| Oxidative stress | Px-12-treated NRK-52E cells | JNK | Zhou et al. (2021) | |
| ECM deposition | Diabetic nephropathy rats | TGF-β1 | Wang et al. (2025) | |
| Isoliquiritigenin | Inflammation | Lipopolysaccharide-treated mice | IκB-α | |
| Inflammation | Diabetic nephropathy mice | TLR4/NF-κB/NLRP3 | Wang et al. (2024) | |
| Inflammation | Cisplatin-treated mice | Smad3/NF-κB | Wen et al. (2020) | |
| Inflammation | Diabetic nephropathy rats | SIRT1/NF-κB | ||
| Inflammation | CKD mice | NF-κB | ||
| Inflammation | High-fat diet rats | TLR4/NF-κB | Yahya and Alshammari (2024) | |
| Inflammation | AKI mice | FPR2 | ||
| Inflammation | CKD rats | JAK2/STAT3 | ; Zhang et al. (2024) | |
| Oxidative stress | Adriamycin-treated rats | SIRT1 | ||
| Autophagy | Caki cells | JAK2/STAT3 | ||
| Autophagy | AKI mice | Unknown | ||
| ECM deposition | Diabetic nephropathy rats | TGF-β1 | ||
| Autophagy | Renal carcinoma cells | PI3K/AKT/mTOR | Xin et al. (2019) | |
| 18β-Glycyrrhetinic acid | Inflammation | Ischemia/reperfusion injury-treated mice | IκB-α | |
| Oxidative stress | Diabetic nephropathy rats | Unknown | ||
| Oxidative stress | Bisphenol A-treated rats | JAK1/STAT1 | ||
| Apoptosis | Cisplatin-treated HK-2 cells | BMP7 | ||
| Other | Hemorrhagic shock rats | Unknown | ||
| 18α-Glycyrrhetinic acid | Inflammation | Excessive fructose-treated tubule epithelial cells | IκB-α | |
| Isoliquiritin | Inflammation | Membranous glomerulonephritis rats | NF-κB | |
| Licochalcone A | Inflammation | AKI mice | IκB-α | |
| Other | Diabetic nephropathy mice | TGF-β1 | ||
| Autophagy | Renal cancer 786-O and 769-P cells | PI3K/AKT/mTOR | Xin and Xu (2018) | |
| Other | Cisplatin-treated renal tubular epithelial cells | mTOR/HIF-1α | Wu et al. (2023) | |
| Isoangustone A | Inflammation | High glucose-treated human mesangial cells | IκB-α | |
| Glabridin | Inflammation | Contrast agent-treated rats | Unknown | |
| Ferroptosis | Diabetic nephropathy rats | AKT | ||
| Other | Hemorrhagic shock-treated rats | Nrf2/HO-1 | ||
| Liquiritigenin | Inflammation | High glucose-treated HBZY-1 cells | Hippo/YAP/TAZ | Wen et al. (2024) |
| Glycyrrhizic acid glycosides | Other | Tripterygium glycosides-treated rats | RhoA/ROCK1 | Zhou et al. (2024) |
Licorice components against nephropathy.
Isoliquiritigenin is the other anti-inflammation component of licorice. Isoliquiritigenin alleviated inflammation by inhibiting the phosphorylation of IκB-α in AKI induced by lipopolysaccharide in mice (Figure 1; Table 1) (). Datta et al. reported that NOD-like receptor thermal protein domain associated protein 3 (NLRP3) could interact with thioredoxin-interacting protein to mediate podocyte injury-induced by nicotine (). Isoliquiritigenin could improve inflammation and oxidative stress through suppressing the Toll-like receptor 4 (TLR4)/NF-κB/NLRP3 signaling pathway in mice with diabetic kidney disease (Table 1) (Wang et al., 2024). Moreover, isoliquiritigenin reduced inflammatory cell infiltration via inhibiting the mothers against decapentaplegic homolog 3 (Smad3)/NF-κB signaling pathway in AKI-induced by cisplatin in mice (Table 1) (Wen et al., 2020). Furthermore, isoliquiritigenin alleviated inflammation and collagen deposition through the silent information regulator 1 (SIRT1)/NF-κB signaling pathway in rats with diabetic nephropathy (Table 1) (). In addition, isoliquiritigenin alleviated inflammation and interstitial fibrosis by inhibiting the NF-κB signaling pathway in CKD mice (Table 1) (). Isoliquiritigenin inhibited inflammation by the TLR4/NF-κB signaling pathway in high-fat diet rats (Table 1) (Yahya and Alshammari, 2024). From these cases, it can conclude that isoliquiritigenin alleviate renal inflammation by inhibiting the NF-κB signaling pathway.
Some other compounds of licorice also show an anti-inflammatory effect by regulating the NF-κB signaling pathway. Recent studies showed that both 18β-glycyrrhetinic acid and 18α-glycyrrhetinic acid alleviated inflammation by suppressing the phosphorylation of IκB-α in the process of nephropathy (Figure 1; Table 1) (; ). In addition, isoliquiritin alleviated inflammation by inhibiting the NF-κB nuclear translocation in rats with membranous glomerulonephritis (Figure 1; Table 1) (; ). Moreover, licochalcone A decreased the production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) through inhibiting the IκB-α degradation in AKI mice (Figure 1; Table 1) (). Moreover, isoangustone A alleviated inflammation and fibrosis by regulating the phosphorylation of IκB-α in human mesangial cells-treated with high glucose (Figure 1; Table 1) ().
In conclusion, licorice mainly improves renal inflammation by inhibiting the NF-κB signaling pathway and the key ingredients include glycyrrhizic acid, 18β-glycyrrhetinic acid, 18α-glycyrrhetinic acid, Isoliquiritigenin, isoliquiritin, licochalcone A, and isoangustone A.
3.1.2 TGF-β1 signaling pathway
When the kidney is injured, the TGF-β1 signaling pathway is activated, thereby promoting inflammation, oxidative stress, autophagy, EMT and ECM deposition. The inhibition of TGF-β1 signaling pathway is the other mechanism of licorice exerting the anti-inflammatory effect. Recent study showed that glycyrrhizic acid alleviated doxorubicin-induced glomerular sclerosis by inhibiting the TGF-β1 signaling pathway in rats (Table 1) (). In addition, glycyrrhizic acid improved the deposition of ECM and glomerular sclerosis by downregulating the TGF-β1 expression in rats (Figure 1; Table 1) (Yu et al., 2010). Moreover, licochalcone A significantly downregulated the TGF-β1 expression in mice with diabetic nephropathy (Figure 1; Table 1) (). Furthermore, glycyrrhetinic acid alleviated renal fibrosis by targeting the TGF-β1 signaling pathway in rats with diabetic nephropathy (Figure 1; Table 1) (Wang et al., 2025).
In conclusion, the anti-inflammatory components of licorice via suppressing the TGF-β1 signaling pathway include glycyrrhizic acid, licochalcone A and glycyrrhetinic acid.
3.1.3 Others
Licorice also shows the anti-inflammatory effects through other mechanism. High mobility group box 1 (HMGB1) shows a proinflammatory effect by binding with TLR4 in the development of many diseases (). Glycyrrhizic acid, a HMGB1 binder, could ameliorate the nicotine-induced podocyte injury via the downregulation of HMBG1 expression through TLR4 inactivation (Table 1) (). Glabridin significantly improved the histology structure of renal tubules and inflammatory cell infiltration in AKI-induced by contrast agent in rats (Table 1) (). In addition, liquiritigenin alleviated inflammation and fibrosis via regulating the Hippo/Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) signaling pathway in HBZY-1 cells-treated with high glucose (Table 1) (Wen et al., 2024). Moreover, glycyrrhizic acid alleviated renal inflammation via the Iinterleukin-25 (IL-25) signaling pathway in mice (Table 1) (). Furthermore, isoliquiritigenin alleviated renal inflammation by targeting formyl peptide receptor 2 (FPR2) in AKI mice (Table 1) (). In addition, isoliquiritigenin improved renal inflammation by inhibiting the Janus kinase 2 (JAK2)/STAT3 signaling pathways in CKD rats (Figure 1; Table 1) (; Zhang et al., 2024).
3.2 Oxidative stress
Oxidative stress is an imbalance between the production of intracellular or intercellular oxidants and the antioxidant defense system. Excessive ROS production cause oxidative stress. The p53 and STAT3 signaling pathways play an important role in oxidative stress ().
The aqueous extract of licorice alleviated the oxidative stress by inhibiting the STAT3 activation in AKI rats (Zhang et al., 2019). In addition, it was revealed that the aqueous extract of licorice and glycyrrhizic acid reduced reactive oxygen species (ROS) production by inhibiting the p53 signaling pathway in HK-2 cells-treated with cisplatin (Figure 1; Table 1) (). Moreover, the aqueous extract of licorice alleviated AKI by eliminating oxygen-nitroso anions and inhibiting protein nitration in rats (Yokozawa et al., 2005). The aqueous extract of licorice alleviated AKI-induced by diosene through its antioxidant activity (). The aqueous extract of licorice alleviated gentamicin-induced AKI by scavenging oxygen free radicals, reducing lipid peroxidation and promoting antioxidant effects (). In addition, the aqueous extract of licorice alleviated diabetic nephropathy through enhancing the kidney antioxidant capacity (). Moreover, the aqueous extract of licorice effectively increase the level of selenium glutathione peroxidase in 5/6 nephrectomy rats (). These results indicate that the aqueous extract of licorice alleviates renal oxidative stress through multiple signaling pathways, involving the STAT3 and p53 signaling pathways.
The ethanol extract and the compounds of licorice also show a therapy effect on alleviating oxidative stress, but the mechanism remains to be further clarified. Kataya et al. reported that the ethanol extract of licorice reduced blood glucose level, improved renal function, and restored the activities of superoxide dismutase in rats with diabetic nephropathy ().
The main anti-oxidative stress components of licorice include ghlycyrrhizic acid, 18α-glycyrrhetinic acid, 18β-glycyrrhetinic acid and isoliquiritigenin. These compounds alleviate kidney injury through multiple mechanisms. Arjumand et al. reported that glycyrrhizic acid alleviated cisplatin-induced AKI through its antioxidant activity (Table 1) (). In addition, glycyrrhizic acid not only inhibited the proliferation of renal carcinoma cells, but also promoted the apoptosis of renal carcinoma cells through inhibiting oxidative stress (Table 1) (Wu et al., 2013). Moreover, glycyrrhizic acid showed a therapy effect on kidney injury by directly targeting HMGB1 in rats (Table 1) (). Yao et al. demonstrated that glycyrrhetinic acid improved oxidative stress of renal tubular cells by regulating the JNK signaling pathway (Figure 1; Table 1) (Zhou et al., 2021). In addition, Cheng et al. found that 18α-glycyrrhetinic acid improved tubular epithelial cell injury by inhibiting oxidative stress, dyslipidemia and inflammation (Table 1) (). Ibtesam et al. revealed that 18β-glycyrrhetinic acid reduced ROS production and restored the antioxidant defenses in diabetic rats (Table 1) (). Ekrem et al. showed that 18β-glycyrrhetinic acid alleviated kidney injury by inhibiting the Janus kinase 1 (JAK1)/signal transducer and activator of transcription 1 (STAT1) signaling pathway (Table 1) (). Moreover, Xiaozhong et al. revealed that isoliquiritigenin alleviated oxidative stress by binding to SIRT1 in the process of kidney injury (Figure 1; Table 1) ().
3.3 Apoptosis
Apoptosis is a programmed cell death, which is indispensable for development and tissue repair. A variety of biomolecules contribute to apoptosis, including bone morphogenetic protein-7 (BMP-7), p38, mitogen-activated protein kinase (MAPK) and caspase-3. The progression of nephropathy shows a close relation with the apoptosis of tubular epithelial cells. The aqueous extract of licorice improved apoptosis by inhibiting the caspase-3 signaling pathway in AKI cells (). In addition, glycyrrhizic acid improved apoptosis and inflammation via suppressing the p38-MAPK signaling pathway in mice with AKI-induced by ischemia-reperfusion (Figure 1; Table 1) (Ye et al., 2014). Moreover, 18β-glycyrrhetinic acid inhibited the apoptosis via upregulating the BMP7 expression in HK-2 cells-treated with cisplatin (Table 1) (). These results indicate that licorice improve apoptosis by regulating the BMP7, p38-MAPK and caspase-3 signaling pathways. The glycyrrhizic acid, 18β-glycyrrhetinic acid and licochalcone A are the main active components of licorice responsible for the anti-apoptosis activity.
3.4 EMT
Under pathological conditions, epithelial cells will lose their innate characteristics and acquire those of mesenchymal cells when the kidney is damaged, which is called EMT. EMT plays an important role in myofibroblasts origin. Myofibroblasts are the key effector cells causing ECM deposition in tissue gap and show a close relation with organ fibrosis and tumor. The Notch 2 signaling pathway plays a crucial role in the process of EMT, and inhibiting EMT is therapeutic for nephropathy.
Recent study showed that glycyrrhetinic acid downregulated the expressions of laminin-1 and α-smooth muscle actin (α-SMA) and upregulated the E-cadherin expression to alleviate fibrosis in mice with diabetic nephropathy (Table 1) (). In addition, the methanol extract of de-glycyrrhizic acidated licorice improved EMT by inhibiting the Notch2 signaling pathway in NRK-52E cells-treated with high glucose, which indicated that some other components of licorice showed an inhibition effect on EMT except for glycyrrhetinic acid ().
3.5 Autophagy
Autophagy is a highly regulated process of organelle degradation and recycling. Some important signaling pathways are involved in the process of autophagy, including the signaling pathways of JAK2/STAT3, protein kinase B (AKT) and phosphatidylinositol 3-kinase (PI3K). Autophagy dysregulation can lead to cancer, and promoting autophagy in renal cancer cells can improve renal cancer.
Kim et al. demonstrated that isoliquiritigenin inhibited the proliferation of Caki cells by suppressing the JAK2/STAT3 signaling pathway (Figure 1; Table 1) (). In addition, isoliquiritigenin upregulated autophagy-related protein 5 (ATG5) expression and downregulated the expressions of mammalian target of rapamycin (mTOR) and AKT in renal carcinoma cells, indicating that isoliquiritigenin exerted anti-cancer activity by inhibiting the PI3K/AKT/mTOR signaling pathway to induce autophagy (Figure 1; Table 1) (Xin et al., 2019). Furthermore, licochalcone A also induced autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway in renal cancer 786-O and 769-P cells to alleviate renal carcinoma (Figure 1; Table 1) (Xin and Xu, 2018). In addition, Rui et al. found that glycyrrhizic acid attenuated kidney injury-induced by tacrolimus via regulating autophagy (Table 1) (). Yun et al. showed that isoliquiritigenin improved AKI by regulating ferritinophagy-mediated ferroptosis in mice with AKI-induced by LPS (Table 1) ().
3.6 ECM deposition
Under pathological conditions, the synthesis rate of ECM is greater than their degradation rate, which leads to ECM deposition and further affects organ function. ECM deposition is the main feature of renal fibrosis. It is crucial to reduce ECM deposition to delay CKD progression to renal failure. The activation of AKT and TGF-β1 signaling pathways contribute to ECM deposition. Therefore, inhibiting the AKT and TGF-β1 signaling pathways can alleviate renal fibrosis.
Li et al. showed that the aqueous and ethanol extracts of roasted licorice reduced ECM deposition by inhibiting the AKT and TGF-β1 signaling pathways in rats with diabetic nephropathy-induced by high glucose (). Li et al. showed that isoliquiritigenin alleviated mesangial ECM deposition by inhibiting the TGF-β1 signaling pathway in rats with diabetic nephropathy-induced by high glucose (Table 1) (). Glycyrrhizic acid improved glomerular sclerosis by reducing ECM deposition in rats (Table 1) (Wang et al., 2006). In addition, glycyrrhetinic acid reduced blood glucose and urinary creatinine levels and alleviate ECM deposition in mice with type 1 and type 2 diabetic nephropathy (Table 1) (). These cases indicate that the compounds of licorice such as isoliquiritigenin and glycyrrhizic acid may be the therapeutic drugs for renal fibrosis.
3.7 Others
Except for the above-mentioned mechanisms, licorice also improves kidney diseases through other pathways.
18β-Glycyrrhetinic acid reduced the levels of urea nitrogen and serum creatinine to alleviate kidney injury in rats with hemorrhagic shock (Table 1) (). In addition, glabridin alleviated diabetic nephropathy by suppressing ferroptosis through the AKT signaling pathway in rat (Figure 1; Table 1) (). Shu et al. reported that glabridin ameliorated hemorrhagic shock induced AKI through activating the Nrf2/HO-1 pathway in rat (Table 1) (). Moreover, glycyrrhizic acid effectively reduced the levels of serum urea nitrogen, creatinine, malondialdehyde and lactate dehydrogenase in rats with acute ischemia/reperfusion renal injury. Glycyrrhizic acid protected against LPS-induced AKI through the PI3K/AKT signaling pathway in mice (Table 1) (). It was reported that glycyrrhizic acid glycosides against tripterygium glycosides-induced nephrotoxicity by the Ras homolog family member A (RhoA)/Rho-associated coiled-coil containing protein kinase 1 (ROCK1) signaling pathway in rats (Table 1) (Zhou et al., 2024). Furthermore, licochalcone A protected renal tubular epithelial cell injury-induced by cisplatin via inhibiting the mTOR/hypoxia-inducible factor 1α (HIF-1α) signaling pathway (Table 1) (Wu et al., 2023).
4 Structure-activity relationships of the active components of licorice
The C3, C7 and C15 positions in glycyrrhizic acid and glycyrrhetinic acid are important for their anti-inflammatory activity (Figure 2). Ni et al. found that the different carbon chain lengths at C3 position of 18α-glycyrrhetinic acid could influence the inhibitory effect on NF-κB activation () (Figure 2). In addition, the hydroxylation at C7 or C15 of 18β-glycyrrhetinic acid could increase the anti-inflammatory activity. Furthermore, the introduction of different heterocycles conjugated with α, β-unsaturated ketones into ring A of 18β-glycyrrhetinic acid can increase apoptosis induction (Figure 2).
FIGURE 2
Glabridin shows low stability due to the pyranobenzene structure in ring A. Choi et al. found that 3″,4″-dihydro-glabridin exhibited better stability than glabridin (Figure 2) ().
Lipase, 3β-hydroxysteroid dehydrogenases (3β-HSD), diacylglycerol acyltransferase and PPAR-γ show a close relationship with inflammation, oxidative stress, apoptosis, EMT, autophagy, and the deposition of ECM. Zeng et al. found that the isopentenyl and hydroxyl substituents at ring A of licorice chalcone were essential for the noncovalent inhibitory potency on pancreatic lipase (Figure 2) (Zeng et al., 2021). In addition, Choi et al. found that glabrol showed a potent inhibitory effect on diacylglycerol acyltransferase, which indicated that the prenyl group was the key structural feature responsible for the inhibitory effect (). Moreover, Kuroda et al. found that the isoprenyl group at C6 and the C2’ hydroxyl group in the aromatic ring C of the isoflavan and isoflavene components of licorice are requirements for the binding activity on PPAR-γ (Figure 2) (). Ye et al. found that the hydrogen bond acceptor in the licorice chalcone molecule was critical for the inhibitory effect on 3β-HSD1 and 3β-HSD2 (Ye et al., 2023). These results may be closely related to the renoprotective effect of licorice components.
5 Discussion
Licorice is a commonly used traditional Chinese medicine in the treatment of nephropathy in clinic. Modern pharmacology studies reveal that the extract and compound of licorice have a therapy effect on nephropathy. Although many compounds have been isolated from licorice, only a few of them have been studied for their nephroprotective effects. In this review, we summarized the existing studies on the nephroprotective effect of licorice. It was found that licorice showed its renoprotective effect through multiple mechanisms, including the properties of anti-inflammatory, anti-oxidative stress, anti-apoptosis, suppressing EMT, reducing ECM deposition and promoting autophagy. The core signaling pathways involved in the renoprotective effect of licorice include the signaling pathways of NF-κB, TGF-β1, STAT3, p53, Notch and PI3K/AKT/mTOR. In addition, both the aqueous and ethanol extracts of licorice have the renoprotective effect. The triterpene components of licorice, such as glycyrrhizic acid and glycyrrhetinic acid, as well as the flavonoids of licorice, including isoliquiritigenin, glabridin, isoliquiritin and licochalcone A, are the main active components of licorice in the treatment of nephropathy. Noteworthily, it was reported that glycyrrhetinic acid could lowered serum potassium concentration in hemodialysis patients (). Therefore, the renoprotective effects of these compounds should be evaluated in clinic to promote them being as drugs.
Increasing evidences suggest that multitarget therapy may offer superior outcomes compared to single-target therapy in the treatment of kidney diseases (). Some components of licorice alleviated kidney diseases through multiple mechanisms. Hongyu Zhao et al. found that glycyrrhizic acid could simultaneously inhibited inflammation, apoptosis and oxidative stress in sepsis-induced kidney injury (Zhao et al., 2016a). In addition, Sanaa M Abd El-Twab et al. found that 18β-glycyrrhetinic acid could attenuate oxidative stress and inflammation to alleviate methotrexate-induced kidney injury (). Moreover, isoliquiritigenin mitigated diabetic kidney disease via oxidative stress and inflammation pathways (Wang et al., 2024). Furthermore, isoliquiritin ameliorated cisplatin-induced kidney injury by improving apoptosis, oxidative and inflammation (). In addition, glabridin could reduce ROS content to alleviate inflammation in hemorrhagic shock-induced AKI (). These results suggest that glycyrrhizic acid, 18β-glycyrrhetinic acid, isoliquiritigenin and glabridin are promising drugs in treating kidney diseases.
Licorice is considered a food-medicine homologous substance, with various benefits for human health (). The mechanisms of licorice against kidney diseases are conducive to elucidating its benefits for kidney health, which will further facilitate the daily dietary application of licorice for patients with nephropathy.
Recently, it was demonstrated that the progression of nephropathy showed a deep association with miRNA, lnRNA and gut microbiota (; ; Yu et al., 2024). However, there is currently no study reporting whether licorice improve kidney injury through regulating the miRNA, lnRNA and gut microbiota, which limit the application of licorice. Thus, the further study of the mechanism of licorice against kidney injury should focus on miRNA, lnRNA and gut microbiota.
A larger number of compounds have been isolated and characterized from licorice. Among them, some may exhibit profound therapy effect on kidney injury. Molecular docking may be a powerful tool to screen the bioactive components of licorice against kidney injury. In addition, artificial intelligence has a significant advantage in screening active components, which saves time and costs in drug development. These powerful tools should be used in the pharmacology study of licorice. For screening the bioactive components from licorice compound prescriptions against kidney diseases, some suggestions are put forward. First, the bioactive components should be screened by activity-guided methods. Second, the network pharmacology prediction combined with experimental validation is effective to discover the bioactive components from licorice compound prescriptions. Third, reverse pharmacokinetics can be used to screen the components of licorice compound prescriptions that accumulate in the kidneys. These components may have renoprotective effects. Fourth, the different licorice components can be combined to target multiple targets simultaneously for nephropathy treatment, thereby identifying effective therapeutic strategies. Fifth, clinical studies on licorice for nephropathy treatment are insufficient, and it is suggested to conduct more clinical trials on licorice for nephropathy treatment.
Although licorice components show renoprotective potential, several obstacles must be overcome before they can be translated into the clinic. First, some licorice components show significant toxicity, such as glycyrrhizic acid, glycyrrhetic acid and isoliquiritigenin. The excessive intake of glycyrrhizic acid could cause mineralocorticoid excess syndrome by the targeting inhibition of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in renal tissue (; ; ). In addition, Lin et al. reported that isoliquiritigenin, licochalcone A, and licochalcone B also had a significant inhibitory effect on 11β-HSD2 (). Moreover, Song et al. reported that isoliquiritigenin had developmental toxicity (). Second, glycyrrhetic acid is prone to degradation under acidic or photochemical conditions (). Third, Zhu et al. found that drying significantly reduced the antioxidant activity of licorice, which might indicate that heat break the native chemical structures of licorice components (Zhu et al., 2025).
Statements
Author contributions
Y-LF: Writing – original draft. LS: Writing – original draft. Y-XJ: Writing – original draft. Y-NW: Writing – review and editing. LC: Writing – review and editing. HC: Writing – review and editing. W-BW: Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by Natural Science Basic Research Program of Shaanxi Province (2023-JC-QN-0892), Shaanxi Provincial Department of Education Special Scientific Research Project (23JK0716), Key R&D Plan Project of Ningxia (No. 2024BEG01006), and Research Project of Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education School of Pharmacy, Ningxia Medical University (No. KFKT202313), Shaanxi Province QinChuangYuan “Scientist + Engineer” Team Construction Project (2022KXJ-015), Xianyang City Innovation Service Capacity Support Program (L2024-CXNL-KJRCTD-KJRC-0007), Xianyang City QinChuangYuan Science and Technology Innovation Special Program (2021ZDZX-NY-0003), Shaanxi Province Key Research and Development Program (2019NY-103), National Natural Science Foundation of China (31872175), Xianyang Normal University Key Research and Development Program (XSYK21042), Shaanxi Natural Science Basic Research Program (2025JC-YBQN-1210).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1672643/full#supplementary-material
References
1
Abd El-TwabS. M.HozayenW. G.HusseinO. E.MahmoudA. M. (2016). 18β-Glycyrrhetinic acid protects against methotrexate-induced kidney injury by up-regulating the Nrf2/ARE/HO-1 pathway and endogenous antioxidants. Ren. Fail38, 1516–1527. 10.1080/0886022X.2016.1216722
2
AksoyN.DoganY.IriadamM.BitirenM.UzerE.OzgonulA.et al (2012). Protective and therapeutic effects of licorice in rats with acute tubular necrosis. J. Ren. Nutr.22, 336–343. 10.1053/j.jrn.2011.07.002
3
AlanaziI. S.EmamM.ElsabaghM.AlkahtaniS.Abdel-DaimM. M. (2021). The protective effects of 18β-glycyrrhetinic acid against acrylamide-induced cellular damage in diabetic rats. Environ. Sci. Pollut. Res. Int.28, 58322–58330. 10.1007/s11356-021-14742-4
4
AlzahraniS.ZaitoneS. A.SaidE.El-SherbinyM.AjwahS.AlsharifS. Y.et al (2020). Protective effect of isoliquiritigenin on experimental diabetic nephropathy in rats: impact on Sirt-1/NFκB balance and NLRP3 expression. Int. Immunopharmacol.87, 106813. 10.1016/j.intimp.2020.106813
5
ArjumandW.SultanaS. (2011). Glycyrrhizic acid: a phytochemical with a protective role against cisplatin-induced genotoxicity and nephrotoxicity. Life Sci.89, 422–429. 10.1016/j.lfs.2011.06.016
6
AtteiaH. H.AlamriE. S.SiragN.ZidanN. S.AljohaniR. H.AlzahraniS.et al (2023). Soluble guanylate cyclase agonist, isoliquiritigenin attenuates renal damage and aortic calcification in a rat model of chronic kidney failure. Life Sci.317, 121460. 10.1016/j.lfs.2023.121460
7
AugustP. (2023). Chronic kidney disease - another step forward. N. Engl. J. Med.388, 179–180. 10.1056/NEJMe2215286
8
BelloA. K.OkpechiI. G.LevinA.YeF.DamsterS.ArrueboS.et al (2024). An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob. Health12, e382–e395. 10.1016/S2214-109X(23)00570-3
9
BlanpainJ. S. (2023). A licorice-flavored edema: a case report of glycyrrhizic acid toxicity from chronic licorice root consumption. Cureus15, e34425. 10.7759/cureus.34425
10
CaoR.LiY.HuX.QiuY.LiS.XieY.et al (2023). Glycyrrhizic acid improves tacrolimus-induced renal injury by regulating autophagy. FASEB J.37, e22749. 10.1096/fj.202201409RR
11
CaréW.GrenetG.SchmittC.MichelS.LangrandJ.Le RouxG.et al (2023). Adverse effects of licorice consumed as food: an update. Rev. Med. Interne44, 487–494. 10.1016/j.revmed.2023.03.004
12
CerqueiraD. M.TayebM.HoJ. (2022). MicroRNAs in kidney development and disease. JCI Insight7, e158277. 10.1172/jci.insight.158277
13
CharltonA.GarzarellaJ.Jandeleit-DahmK. a.M.JhaJ. C. (2020). Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology (Basel)10, 18. 10.3390/biology10010018
14
ChauhanP.SharmaH.KumarU.MayachariA.SangliG.SinghS. (2020). Protective effects of Glycyrrhiza glabra supplementation against methotrexate-induced hepato-renal damage in rats: an experimental approach. J. Ethnopharmacol.263, 113209. 10.1016/j.jep.2020.113209
15
ChenY.DabbasW.GangemiA.BenedettiE.LashJ.FinnP. W.et al (2021). Obesity management and chronic kidney disease. Semin. Nephrol.41, 392–402. 10.1016/j.semnephrol.2021.06.010
16
ChenL.LiangB.XiaS.WangF.LiZ.ShaoJ.et al (2023). Emodin promotes hepatic stellate cell senescence and alleviates liver fibrosis via a nuclear receptor (Nur77)-mediated epigenetic regulation of glutaminase 1. Br. J. Pharmacol.180, 2577–2598. 10.1111/bph.16156
17
ChengX.QiuL.WangF. (2020). 18α-Glycyrrhetinic acid (GA) ameliorates fructose-induced nephropathy in mice by suppressing oxidative stress, dyslipidemia and inflammation. Biomed. Pharmacother.125, 109702. 10.1016/j.biopha.2019.109702
18
ChoiJ. H.ChoiJ. N.LeeS. Y.LeeS. J.KimK.KimY. K. (2010). Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice. Arch. Pharm. Res.33, 237–242. 10.1007/s12272-010-0208-3
19
ChoiL. S.JoI. G.KangK. S.ImJ. H.KimJ.KimJ.et al (2021). Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int. J. Obes. (Lond)45, 130–142. 10.1038/s41366-020-00686-1
20
CuiX.LouL.ZhangY.YanB. (2023). Study of the distribution of Glycyrrhiza uralensis production areas as well as the factors affecting yield and quality. Sci. Rep.13, 5160. 10.1038/s41598-023-31946-5
21
DarendeliogluE.CaglayanC.KüçüklerS.Bayavİ.KandemirF. M.AynaA.et al (2025). 18β-Glycyrrhetinic acid mitigates bisphenol A-induced liver and renal damage: inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosis. Food Chem. Toxicol.196, 115218. 10.1016/j.fct.2024.115218
22
DattaS.RahmanM. A.KokaS.BoiniK. M. (2024a). High mobility group box 1 (HMGB1) mediates nicotine-induced podocyte injury. Front. Pharmacol.15, 1540639. 10.3389/fphar.2024.1540639
23
DattaS.RahmanM. A.KokaS.BoiniK. M. (2024b). High mobility group box 1 (HMGB1): molecular signaling and potential therapeutic strategies. Cells13, 1946. 10.3390/cells13231946
24
DattaS.RahmanM. A.KokaS.BoiniK. M. (2025). Mitigation of nicotine-induced podocyte injury through inhibition of thioredoxin interacting protein. Biomed. Pharmacother.187, 118110. 10.1016/j.biopha.2025.118110
25
DingY.BrandE.WangW.ZhaoZ. (2022). Licorice: resources, applications in ancient and modern times. J. Ethnopharmacol.298, 115594. 10.1016/j.jep.2022.115594
26
DuH. S.ZhangR. B.WangP.WangX. P.PangS. G. (2010). Renal protective effects of licorice extracts in diabetic rats. J. Shandong Univ. (Health Sci)4, 1–4. (in Chinese).
27
EmaraN. A.MahmoudM. F.El FayoumiH. M.MahmoudA. a.A. (2021). The renoprotective effect of glycyrrhizic acid in insulin-resistant rats exposed to aluminum involves the inhibition of TLR4/NF-κB signaling pathway. Naunyn Schmiedeb. Arch. Pharmacol.394, 863–872. 10.1007/s00210-020-02012-y
28
FareseS.KruseA.PaschA.DickB.FreyB. M.UehlingerD. E.et al (2009). Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney Int.76, 877–884. 10.1038/ki.2009.269
29
FearnA.SitumorangG. R.FoxC.OakleyF.HowarthR.WilsonC. L.et al (2017). The NF-κB1 is a key regulator of acute but not chronic renal injury. Cell Death Dis.8, e2883. 10.1038/cddis.2017.233
30
FengY. L.ChenD. Q.VaziriN. D.GuoY.ZhaoY. Y. (2020). Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med. Res. Rev.40, 54–78. 10.1002/med.21596
31
FengY. L.WangW. B.NingY.ChenH.LiuP. (2021). Small molecules against the origin and activation of myofibroblast for renal interstitial fibrosis therapy. Biomed. Pharmacother.139, 111386. 10.1016/j.biopha.2021.111386
32
FengY. L.YangY.ChenH. (2022). Small molecules as a source for acute kidney injury therapy. Pharmacol. Ther.237, 108169. 10.1016/j.pharmthera.2022.108169
33
FrancisA.HarhayM. N.OngA. C. M.TummalapalliS. L.OrtizA.FogoA. B.et al (2024). Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol.20, 473–485. 10.1038/s41581-024-00820-6
34
GeQ.LiangY.WangX. Y.SuY.WangH. H.WeiY. Z.et al (2024). Protective effect of 18β-glycyrrhetinic acid on the kidneys of rats with hemorrhagic shock. Jilin Med. J.5 (6), 1271–1275. (in Chinese).
35
HaoM.LvY.LiuS.GuoW. (2024). The new challenge of obesity - obesity-associated nephropathy. Diabetes Metab. Syndr. Obes.17, 1957–1971. 10.2147/DMSO.S433649
36
HaoX.PengR.GuanM.ZhangH.GuoY.ShalapyN. M.et al (2024). The food and medicinal homological resources benefiting patients with hyperlipidemia: categories, functional components, and mechanisms. Food and Med. Homology1, 9420003. 10.26599/fmh.2024.9420003
37
HsuY. C.ChangP. J.TungC. W.ShihY. H.NiW. C.LiY. C.et al (2020). De-glycyrrhizinated licorice extract attenuates high glucose-stimulated renal tubular epithelial-mesenchymal transition via suppressing the Notch2 signaling pathway. Cells9, 125. 10.3390/cells9010125
38
HuJ.LiuJ. (2016). Licochalcone A attenuates lipopolysaccharide-induced acute kidney injury by inhibiting NF-κB activation. Inflammation39, 569–574. 10.1007/s10753-015-0281-3
39
HuangY. H.YuL.ZhangL.HaoZ. H.WangL. N.DengY. (2009). Protective effects of glycyrrhizin on experimental transforming growth factorβ1. Prog. Mod. Biomed.5, 3262–3265+3192. (in Chinese).
40
HuangX.ShiY.ChenH.LeR.GongX.XuK.et al (2020). Isoliquiritigenin prevents hyperglycemia-induced renal injuries by inhibiting inflammation and oxidative stress via SIRT1-dependent mechanism. Cell Death Dis.11, 1040. 10.1038/s41419-020-03260-9
41
IatcuC. O.SteenA.CovasaM. (2021). Gut microbiota and complications of type-2 diabetes. Nutrients14, 166. 10.3390/nu14010166
42
JavedA.MahmoodT.TiwariR.AhsanF.AnsariV. A.BanoS.et al (2025). Navigating nephropathy and nephrotoxicity: understanding pathophysiology unveiling clinical manifestations, and exploring treatment approaches. J. Basic Clin. Physiol. Pharmacol.36, 69–93. 10.1515/jbcpp-2024-0220
43
JiangY.CaiC.ZhangP.LuoY.GuoJ.LiJ.et al (2022). Transcriptional profile changes after treatment of ischemia reperfusion injury-induced kidney fibrosis with 18β-glycyrrhetinic acid. Ren. Fail44, 660–671. 10.1080/0886022X.2022.2061998
44
JinY. X.ZhangY.LiuT. J.ZhangY. K. (2016). Effects of licorice aqueous extract on C-BSA nephritis in rat model. World Clin. Drugs37, 29–32. (in Chinese). 10.13683/j.wph.2016.01.008
45
JuS. M.KimM. S.JoY. S.JeonY. M.BaeJ. S.PaeH. O.et al (2017). Licorice and its active compound glycyrrhizic acid ameliorates cisplatin-induced nephrotoxicity through inactivation of p53 by scavenging ROS and overexpression of p21 in human renal proximal tubular epithelial cells. Eur. Rev. Med. Pharmacol. Sci.21, 890–899.
46
JungM. H.IhmS. H. (2023). Obesity-related hypertension and chronic kidney disease: from evaluation to management. Kidney Res. Clin. Pract.42, 431–444. 10.23876/j.krcp.23.072
47
KatayaH. H.HamzaA. A.RamadanG. A.KhasawnehM. A. (2011). Effect of licorice extract on the complications of diabetes nephropathy in rats. Drug Chem. Toxicol.34, 101–108. 10.3109/01480545.2010.510524
48
KimD. H.ParkJ. E.ChaeI. G.ParkG.LeeS.ChunK. S. (2017). Isoliquiritigenin inhibits the proliferation of human renal carcinoma caki cells through the ROS-mediated regulation of the Jak2/STAT3 pathway. Oncol. Rep.38, 575–583. 10.3892/or.2017.5677
49
KurodaM.MimakiY.SashidaY.MaeT.KishidaH.NishiyamaT.et al (2003). Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice. Bioorg Med. Chem. Lett.13, 4267–4272. 10.1016/j.bmcl.2003.09.052
50
LiJ.KangS. W.KimJ. L.SungH. Y.KwunI. S.KangY. H. (2010a). Isoliquiritigenin entails blockade of TGF-beta1-SMAD signaling for retarding high glucose-induced mesangial matrix accumulation. J. Agric. Food Chem.58, 3205–3212. 10.1021/jf9040723
51
LiJ.LeeY. S.ChoiJ. S.SungH. Y.KimJ. K.LimS. S.et al (2010b). Roasted licorice extracts dampen high glucose-induced mesangial hyperplasia and matrix deposition through blocking Akt activation and TGF-beta signaling. Phytomedicine17, 800–810. 10.1016/j.phymed.2010.02.004
52
LiJ.LimS. S.LeeE. S.GongJ. H.ShinD.KangI. J.et al (2011). Isoangustone A suppresses mesangial fibrosis and inflammation in human renal mesangial cells. Exp. Biol. Med. (Maywood)236, 435–444. 10.1258/ebm.2010.010325
53
LiX. Q.ShenY.ShiJ. (2018). Curative effect of glycyrrhetinicacid for diabetic nephropathy animal model. J. Clin. Nephrol.18, 434–439. (in Chinese). 10.3969/j.issn.1671-2390.2018.07.011
54
LiL.ZhangY.WangZ.ChenX.FangM. (2024). Glycyrrhizin attenuates renal inflammation in a mouse Con A-hepatitis model via the IL-25/M2 axis. Ren. Fail46, 2356023. 10.1080/0886022X.2024.2356023
55
LiaoY.TanR. Z.LiJ. C.LiuT. T.ZhongX.YanY.et al (2020). Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting Mincle/Syk/NF-Kappa B signaling pathway. Drug Des. Devel Ther.14, 1455–1468. 10.2147/DDDT.S243420
56
LinH.SuM.WenC.TangY.LiH.WuY.et al (2024). Chalcones from plants cause toxicity by inhibiting human and rat 11β-hydroxysteroid dehydrogenase 2: 3D-quantitative structure-activity relationship (3D-QSAR) and in silico docking analysis. Food Chem. Toxicol.184, 114415. 10.1016/j.fct.2023.114415
57
LiuJ. Q.ZhuY. X. (2018). Protective effects and main mechanisms of glabridin on rats with contrast-induced nephropathy. J. Emerg. Tradit. Chin. Med.27, 2132–2136. (in Chinese). 10.3969/j.issn.1004-745X.2018.12.019
58
LiuS. J.ZhaoX.WangY. G. (2018). Research on the medication patterns of traditional Chinese medicine in the treatment of renal interstitial fibrosis. Lishizhen Med. Mater Med. Res.29, 3048–3049. (in Chinese). 10.3969/j.issn.1008-0805.2018.12.082
59
LiuY.XuX.XuR.ZhangS. (2019). Renoprotective effects of isoliquiritin against cationic bovine serum albumin-induced membranous glomerulonephritis in experimental rat model through its anti-oxidative and anti-inflammatory properties. Drug Des. Devel Ther.13, 3735–3751. 10.2147/DDDT.S213088
60
LiuW. J.NanY.LuY. M.YuanL. (2020). Protective effects of glycyrrhetinic acid on early and mid-stage renal fibrosis in kk-Ay diabetic mice. Yunnan J. Tradit. Chin. Med. Mater Med.41, 72–78. (in Chinese). 10.3969/j.issn.1007-2349.2020.03.023
61
LuZ.LiuW.GaoH.ChenW.GeW.LiF.et al (2021). Traditional Chinese medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLoS One16, e0251131. 10.1371/journal.pone.0251131
62
LuoZ.LiT.GaoQ.ChenY.SuG.ZhaoY. (2021). Impact of licochalcone A on the progression of diabetic nephropathy in type 2 diabetes mellitus of C57BL/6 mice. Food Funct.12, 10676–10689. 10.1039/d1fo01630j
63
MaT.HuangC.MengX.LiX.ZhangY.JiS.et al (2016). A potential adjuvant chemotherapeutics, 18β-glycyrrhetinic acid, inhibits renal tubular epithelial cells apoptosis via enhancing BMP-7 epigenetically through targeting HDAC2. Sci. Rep.6, 25396. 10.1038/srep25396
64
MakinoT. (2021). Exploration for the real causative agents of licorice-induced pseudoaldosteronism. J. Nat. Med.75, 275–283. 10.1007/s11418-021-01484-3
65
MusharrafS. G.KanwalN.ArfeenQ. U. (2013). Stress degradation studies and stability-indicating TLC-densitometric method of glycyrrhetic acid. Chem. Cent. J.7, 9. 10.1186/1752-153X-7-9
66
Na TakuathungM.SakuludomkanW.KhatsriR.DukaewN.KraivisitkulN.AhmadmusaB.et al (2022). Adverse effects of angiotensin-converting enzyme inhibitors in humans: a systematic review and meta-analysis of 378 randomized controlled trials. Int. J. Environ. Res. Public Health19, 8373. 10.3390/ijerph19148373
67
NiQ.GaoY.YangX.ZhangQ.GuoB.HanJ.et al (2022). Analysis of the network pharmacology and the structure-activity relationship of glycyrrhizic acid and glycyrrhetinic acid. Front. Pharmacol.13, 1001018. 10.3389/fphar.2022.1001018
68
OhH.ChoiA.SeoN.LimJ. S.YouJ. S.ChungY. E. (2021). Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on post-contrast acute kidney injury. Sci. Rep.11, 15625. 10.1038/s41598-021-94928-5
69
PanzarinoV.LesserJ.CassaniF. A. (2022). Pediatric chronic kidney disease. Adv. Pediatr.69, 123–132. 10.1016/j.yapd.2022.03.008
70
PeiZ.WuM.YuH.LongG.GuiZ.LiX.et al (2022). Isoliquiritin ameliorates cisplatin-induced renal proximal tubular cell injury by antagonizing apoptosis, oxidative stress and inflammation. Front. Med. (Lausanne)9, 873739. 10.3389/fmed.2022.873739
71
RosalesI. A.ZhouI. Y.AyI.SojoodiM.SiseM. E.GaleE. M. (2024). Imaging kidney inflammation using an oxidatively activated MRI probe. Kidney Int.106, 671–678. 10.1016/j.kint.2024.05.027
72
Rui-ZhiT.Ke-HuanX.YuanL.XiaoL.Bing-WenZ.Tong-TongL.et al (2022). Renoprotective effect of isoliquiritigenin on cisplatin-induced acute kidney injury through inhibition of FPR2 in macrophage. J. Pharmacol. Sci.148, 56–64. 10.1016/j.jphs.2021.10.001
73
SakrS.El-KenawyA.El-SahraD. (2013). Metiram-induced nephrotoxicity in albino mice: effect of licorice aqueous extract. Environ. Toxicol.28, 372–379. 10.1002/tox.20728
74
SanzA. B.Sanchez-NiñoM. D.RamosA. M.OrtizA. (2023). Regulated cell death pathways in kidney disease. Nat. Rev. Nephrol.19, 281–299. 10.1038/s41581-023-00694-0
75
ShuL.ZhangZ.WangN.YinQ.ChaoY.GeX. (2025). Glabridin ameliorates hemorrhagic shock induced acute kidney injury by activating Nrf2/HO-1 pathway. Biochim. Biophys. Acta Mol. Basis Dis.1871, 167810. 10.1016/j.bbadis.2025.167810
76
SongZ.ZhangY.ZhangH.RajendranR. S.WangR.HsiaoC. D.et al (2020). Isoliquiritigenin triggers developmental toxicity and oxidative stress-mediated apoptosis in zebrafish embryos/larvae via Nrf2-HO1/JNK-ERK/mitochondrion pathway. Chemosphere246, 125727. 10.1016/j.chemosphere.2019.125727
77
SrivastavaA.TomarB.SharmaD.RathS. K. (2023). Mitochondrial dysfunction and oxidative stress: role in chronic kidney disease. Life Sci.319, 121432. 10.1016/j.lfs.2023.121432
78
TanH.ChenJ.LiY.LiY.ZhongY.LiG.et al (2022). Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. Mol. Med.28, 58. 10.1186/s10020-022-00481-w
79
TangY.WangC.WangY.ZhangJ.WangF.LiL.et al (2018). Isoliquiritigenin attenuates LPS-induced AKI by suppression of inflammation involving NF-κB pathway. Am. J. Transl. Res.10, 4141–4151.
80
TangY.LuoH.XiaoQ.LiL.ZhongX.ZhangJ.et al (2021). Isoliquiritigenin attenuates septic acute kidney injury by regulating ferritinophagy-mediated ferroptosis. Ren. Fail43, 1551–1560. 10.1080/0886022X.2021.2003208
81
VivanteA. (2024). Genetics of chronic kidney disease. N. Engl. J. Med.391, 627–639. 10.1056/NEJMra2308577
82
VoroneanuL.CovicA.TesarV.KanbayM. (2025). Advances in multitarget therapeutic approaches for immune-mediated glomerular diseases. Life (Basel)15 (2), 243. 10.3390/life15020243
83
WahabS.AnnaduraiS.AbullaisS. S.DasG.AhmadW.AhmadM. F.et al (2021). Glycyrrhiza glabra (Licorice): a comprehensive review on its phytochemistry, biological activities, clinical evidence and toxicology. Plants (Basel)10, 2751. 10.3390/plants10122751
84
WangL. N.YuL.ZhangL.HaoZ. H.ZhaoD.ZhangY. X. (2006). Protective effects of glycyrrhizin on adriamycin nephropathy in rats. J. Integr. Med.4, 413–417. (in Chinese). 10.3736/jcim20060419
85
WangY.FengY.LiM.YangM.ShiG.XuanZ.et al (2022). Traditional Chinese medicine in the treatment of chronic kidney diseases: theories, applications, and mechanisms. Front. Pharmacol.13, 917975. 10.3389/fphar.2022.917975
86
WangY.YangJ.ChangX.XueY.LiuG.ZhangT.et al (2024). Isoliquiritigenin alleviates diabetic kidney disease via oxidative stress and the TLR4/NF-κB/NLRP3 inflammasome pathway. Mol. Nutr. Food Res.68, e2400215. 10.1002/mnfr.202400215
87
WangY.HeW.RenP.ZhaoL.ZhengD.JinJ. (2025). Carthamin yellow-loaded glycyrrhetinic acid liposomes alleviate interstitial fibrosis in diabetic nephropathy. Ren. Fail47, 2459356. 10.1080/0886022X.2025.2459356
88
WenD.LiaoY.LiJ. C.ZhangY. W.FanJ. M. (2020). Effect of isoliquiritigenin on cisplatin-induced acute kidney injury in mice with inflammation through the Smad3/Arid2-IR/NF-κB axis. Chin. J. Comp. Med.30, 25–30+46. (in Chinese). 10.3969/j.issn.1671-7856.2020.06.004
89
WenY.FuR.LiuC.QiuY. C. (2024). Impacts of liquiritigenin on high glucose-induced inflammatory response and fibrosis in glomerular mesangial cells by regulating Hippo/YAP/TAZ signaling pathway. Med. J. West China36, 1131–1136. (in Chinese).
90
WuZ. Y.NiuL. Y.LiangX. A. (2010). Analysis of chemical constituents and pharmacological effects of licorice. Henan Tradit. Chin. Med.30, 1235–1236. (in Chinese).
91
WuB.YuanJ.HuangQ.YangW.ZhaoH. (2013). Effects of liquiritigenin on proliferation, apoptosis and invasion of renal cell carcinoma 786-0cell line. Jiangsu Med. J.39, 2804–2806+2796. (in Chinese).
92
WuC. H.ChenA. Z.YenG. C. (2015). Protective effects of glycyrrhizic acid and 18β-glycyrrhetinic acid against cisplatin-induced nephrotoxicity in BALB/c mice. J. Agric. Food Chem.63, 1200–1209. 10.1021/jf505471a
93
WuR. X.TianS.XiongJ. Q.TianX. F.HuangX. Y. (2023). Protective mechanism of licochalcone A on cisplatin induced renal tubular epithelial cells by regulating mTOR/HIF-1α pathway. Chin. J. Immunol.39, 1420–1424. (in Chinese).
94
XieK.CaoH.LingS.ZhongJ.ChenH.ChenP.et al (2025). Global, regional, and national burden of chronic kidney disease, 1990-2021: a systematic analysis for the global burden of disease study 2021. Front. Endocrinol.16, 1526482. 10.3389/fendo.2025.1526482
95
XinH.XuW. (2018). Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/AKT/mTOR signaling pathway. China J. Chin. Mater Med.43, 3545–3552. (in Chinese). 10.19540/j.cnki.cjcmm.20180427.001
96
XinH.SunP. R.SongP.XuW. (2019). Anticancer effect of isoliquiritigenin on human clear cell renal cell carcinoma 786-O cells and molecular mechanism. Chin. J. Exp. Tradit. Med. Formulae25, 83–89. (in Chinese). 10.13422/j.cnki.syfjx.20191122
97
YahyaM. A.AlshammariG. M.OsmanM. A.Al-HarbiL. N.AlotaibiS. N. (2024). Isoliquiritigenin prevents the development of nephropathy by an HFD in rats through the induction of antioxidant production and inhibition of the MD-2/TLR4/NF-κB pathway. Biology (Basel)13, 984. 10.3390/biology13120984
98
YanZ.ShaoT. (2024). Chronic inflammation in chronic kidney disease. Nephron148, 143–151. 10.1159/000534447
99
YeS.ZhuY.MingY.SheX.LiuH.YeQ. (2014). Glycyrrhizin protects mice against renal ischemia-reperfusion injury through inhibition of apoptosis and inflammation by downregulating p38 mitogen-activated protein kinase signaling. Exp. Ther. Med.7, 1247–1252. 10.3892/etm.2014.1570
100
YeL.SuM.QiaoX.WangS.ZhengK.ZhuY.et al (2023). Chalcone derivatives from licorice inhibit human and rat gonadal 3β-hydroxysteroid dehydrogenases as therapeutic uses. J. Ethnopharmacol.317, 116690. 10.1016/j.jep.2023.116690
101
YokozawaT.ChoE. J.RhyuD. Y.ShibaharaN.AoyagiK. (2005). Glycyrrhizae Radix attenuates peroxynitrite-induced renal oxidative damage through inhibition of protein nitration. Free Radic. Res.39, 203–211. 10.1080/10715760400027888
102
YuL.ZhangL.HaoZ. H.WangL. N.DengY.ZhangY. X. (2010). Renoprotective effects of glycyrrhizin on experimental glomerulosclerosis in rats. Chin. Tradit. Herb. Drugs41, 250–255. (in Chinese).
103
YuS.LiY.LuX.HanZ.LiC.YuanX.et al (2024). The regulatory role of miRNA and lncRNA on autophagy in diabetic nephropathy. Cell Signal118, 111144. 10.1016/j.cellsig.2024.111144
104
ZengF.WuW.ZhangY.PanX.DuanJ. (2021). Rapid screening of lipase inhibitors in licorice extract by using porcine pancreatic lipase immobilized on Fe3O4 magnetic nanoparticles. Food Funct.12, 5650–5657. 10.1039/d0fo03352a
105
ZhangM.WangC.CaiH. L.WenJ.FangP. F. (2019). Licorice extracts attenuate nephrotoxicity induced by brucine through suppression of mitochondria apoptotic pathway and STAT3 activation. Curr. Med. Sci.39, 890–898. 10.1007/s11596-019-2126-z
106
ZhangZ.DengS.ShiQ. (2024). Isoliquiritigenin attenuates high glucose-induced proliferation, inflammation, and extracellular matrix deposition in glomerular mesangial cells by suppressing JAK2/STAT3 pathway. Naunyn Schmiedeb. Arch. Pharmacol.397, 123–131. 10.1007/s00210-023-02598-z
107
ZhaoH.LiuZ.ShenH.JinS.ZhangS. (2016a). Glycyrrhizic acid pretreatment prevents sepsis-induced acute kidney injury via suppressing inflammation, apoptosis and oxidative stress. Eur. J. Pharmacol.781, 92–99. 10.1016/j.ejphar.2016.04.006
108
ZhaoH.ZhaoM.WangY.LiF.ZhangZ. (2016b). Glycyrrhizic acid attenuates sepsis-induced acute kidney injury by inhibiting NF-κB signaling pathway. Evid. Based Complement. Altern. Med.2016, 8219287. 10.1155/2016/8219287
109
ZhaoT. Q.LiY.ZhangM.ZhaoM. C.CaoX.HouS. Z. (2023). Glycyrrhizic acid protects glomerular podocytes induced by high glucose by modulating SNARK/AMPK signaling pathway. Curr. Med. Sci.43, 696–707. 10.1007/s11596-023-2765-y
110
ZhouY.GaoL.XiaP.ZhaoJ.LiW.ZhouY.et al (2021). Glycyrrhetinic acid protects renal tubular cells against oxidative injury via reciprocal regulation of JNK-connexin 43-Thioredoxin 1 signaling. Front. Pharmacol.12, 619567. 10.3389/fphar.2021.619567
111
ZhouL.YangY.FuX.XiaB.LiC.LuC.et al (2024). The protective effect and molecular mechanism of glycyrrhizic acid glycosides against tripterygium glycosides induced nephrotoxicity based on the RhoA/ROCK1 signalling pathway. J. Ethnopharmacol.319, 117100. 10.1016/j.jep.2023.117100
112
ZhuX.XueJ.LiuZ.DaiW.XiangJ.XuH.et al (2022). The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: an observational study using the MIMIC database. Front. Pharmacol.13, 918385. 10.3389/fphar.2022.918385
113
ZhuL.LiM.ZhangX.ZhangQ.YangX.GengZ. (2025). Metabolomics reveals the differential regulatory mechanisms of quality and flavonoid biosynthetic pathways during the drying process of varieties licorice. Food Chem. X28, 102631. 10.1016/j.fochx.2025.102631
Summary
Keywords
licorice, nephropathy, chronic kidney diseases, Glycyrrhiza uralenssis fish., Glycyrrhiza inflate bat., Glycyrrhiza glabra L
Citation
Feng Y-L, Shui L, Jiang Y-X, Wang Y-N, Chen L, Chen H and Wang W-B (2025) Licorice in nephropathy treatment: phytochemical compositions and pharmacological mechanisms. Front. Pharmacol. 16:1672643. doi: 10.3389/fphar.2025.1672643
Received
24 July 2025
Revised
22 October 2025
Accepted
27 October 2025
Published
21 November 2025
Volume
16 - 2025
Edited by
Ayman M. Mahmoud, Manchester Metropolitan University, United Kingdom
Reviewed by
Sayantap Datta, Johns Hopkins University, United States
Anupriya Singh, Institute of Medical Sciences, India
Updates
Copyright
© 2025 Feng, Shui, Jiang, Wang, Chen, Chen and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ya-Long Feng, fengyalong2012@163.com; Hua Chen, chenhnwu@163.com; Wen-Bo Wang, wenbowang@163.com
‡ These authors share first authorship
ORCID: Ya-Long Feng, orcid.org/0000-0001-5207-5010; Hua Chen, orcid.org/0000-0001-5564-4610
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.